HCG (Testicular Tumor) Test · Blood

If you have been diagnosed with testicular cancer, or you are being monitored after treatment, one number on your lab report carries outsized weight. hCG (human chorionic gonadotropin) is a hormone that healthy men produce in only trace amounts. When a testicular tumor starts making it, your blood level rises, sometimes weeks before a scan would show anything wrong.

That speed matters. In men with nonseminomatous germ cell tumors (a group of testicular cancers made up of several different cell types), rising hCG or AFP (alpha-fetoprotein, another tumor marker) detected relapse or incomplete response an average of four to eight weeks before doctors could confirm it by any other means. Tracking this number gives you and your medical team a window of time to act.

Why Testicular Tumors Make hCG

hCG is normally produced in large quantities during pregnancy. It is a protein made of two linked chains, called the alpha and beta subunits. The beta subunit is what makes hCG distinct from other hormones, and labs often measure it specifically as beta-hCG.

Testicular germ cell tumors can contain specialized cells called syncytiotrophoblasts, the same cell type that produces hCG in the placenta. These cells appear most commonly in choriocarcinoma (a rare, aggressive tumor subtype), but they also show up in embryonal carcinoma (another mixed-cell subtype) and, less frequently, in seminoma (the most common single type of testicular cancer). The more of these cells a tumor contains, the higher your hCG tends to be.

Beyond just leaking into the bloodstream, hCG appears to actively help tumors grow. In a study of 101 men with testicular germ cell tumors, those with hCG levels at or above 25 mIU/mL (a standard lab unit for this test) had significantly more blood vessel formation inside their tumors. This connection between hCG and new blood vessel growth (a process called angiogenesis) may be one reason higher hCG correlates with more aggressive disease.

Which Tumors Raise hCG

Not all testicular cancers produce hCG equally. The pattern depends on the tumor type, and understanding this matters for interpreting your result.

This means a normal hCG does not rule out testicular cancer. A majority of seminomas, roughly 60% or more depending on the assay, produce no detectable hCG. If your doctor suspects testicular cancer based on a physical exam or ultrasound, a normal hCG alone should never be taken as an all-clear.

Diagnostic Accuracy

hCG is highly specific but only moderately sensitive. When it is elevated in a man with a testicular mass, the reading is almost certainly meaningful. The problem is that it misses many tumors entirely.

A systematic review of tumor markers for recurrent testicular cancer found that AFP and hCG together have specificity between 90% and 100%, meaning false alarms are rare. But sensitivity for detecting recurrence is often low, meaning many relapses show no marker elevation at all. In 126 men with nonseminomatous tumors, combining hCG and AFP caught 86% of relapses and partial responses, with specificity near 98% to 100%.

One important technical detail: measuring the free beta subunit of hCG separately from intact hCG increases detection rates substantially. In one study of 351 patients, testing for free beta-hCG raised the proportion of marker-positive seminomas from 17% to 57%, and marker-positive relapses from 32% to 59%. If your lab only reports total or intact hCG without a separate free beta-hCG measurement, some tumors may be missed.

Reference Ranges

For nonpregnant men, the normal range for hCG is very low. The exact numbers depend on the assay your lab uses, and this variation between assays is a real issue in testicular cancer care. Different commercial kits detect different forms of the hCG molecule and can give different results on the same blood sample.

These values come from assays described in published research using specific platforms (such as the AutoDelfia assay). Your lab may use a different system with slightly different cutpoints. What matters most is comparing your results over time within the same lab and the same assay, rather than treating any single threshold as absolute.

For cancer staging and prognosis, clinicians look at how many times your hCG exceeds the upper limit of normal. Higher multiples correlate with larger tumors, more advanced disease, and worse outcomes. In the Swiss, Austrian, and German Testicular Cancer Cohort Study of 793 patients, beta-hCG was abnormal at diagnosis in 57% of nonseminomatous tumors and 24% of seminomas.

When Results Can Be Misleading

False-positive hCG results are surprisingly common in this setting and have led to real harm, including unnecessary chemotherapy in documented cases.

• LH cross-reactivity: After orchiectomy (surgical removal of a testicle), your body often increases production of LH (luteinizing hormone), a closely related hormone. Some commercial beta-hCG assays cannot fully distinguish LH from hCG, producing falsely elevated readings. In one study, 41% of men with a single remaining testicle and 70% of men with no testes had at least one false-positive hCG result from this effect alone.
• Heterophilic antibodies (rogue antibodies that interfere with lab equipment): Some people have antibodies in their blood that bind to assay components and produce persistent false elevations. In one published case, a man received unnecessary second-line and third-line chemotherapy before the false positive was recognized. Testing the same sample with an alternative assay method can resolve this.
• Low testosterone after treatment: Men who have undergone orchiectomy or chemotherapy often develop low testosterone (hypogonadism) and compensatory rises in pituitary hormones, including LH, which can mimic a mild hCG elevation on certain assays.

If your hCG is mildly elevated but you have no other evidence of active disease, your doctor should consider repeating the test with a different assay method and checking your LH and testosterone levels before concluding that the tumor has returned.

Newer Markers on the Horizon

A blood test measuring a small RNA molecule called miR-371a-3p has consistently outperformed hCG and AFP in head-to-head studies. In a prospective multicenter study of 874 patients, the miR-371a-3p test (called the M371 test) achieved sensitivity above 90% and specificity above 90%, substantially better than classical markers. A combined panel adding a DNA-based marker (hypermethylated RASSF1A, which detects a chemical tag on tumor DNA) to miR-371a-3p reached 100% sensitivity in one cohort of 138 patients.

These newer tests are not yet widely available in routine clinical practice, but they are moving toward it. For now, hCG remains a standard part of testicular cancer care, and its value is greatest when interpreted alongside AFP, LDH (lactate dehydrogenase, an enzyme that rises with tissue damage), imaging, and clinical context.

Tracking Your Trend

A single hCG reading is far less informative than a series of readings over time. In a large prospective cohort of 793 patients, 15.6% had at least one false-positive marker event during follow-up. Many of these were isolated blips that normalized on the next draw. True relapses, by contrast, show a consistent rising pattern.

hCG has a biological half-life of about 24 to 36 hours, meaning your blood level drops by half roughly every day to day and a half. After successful surgery or chemotherapy, your level should fall predictably along that curve. If it plateaus or rises instead of falling, that is a stronger signal than any single absolute number. Serial measurements, spaced according to your treatment phase, are the backbone of monitoring.

During active surveillance after initial treatment, hCG is typically checked every one to two months in the first year, then every two to three months in the second year, tapering to every six months after that. If you are starting a new treatment, more frequent checks (every two to four weeks) help you and your team see the trajectory clearly.

What to Do with an Abnormal Result

If your hCG comes back elevated, the next step depends on the context.

• New elevation during surveillance: Retest within one to two weeks. If still rising, order AFP and LDH alongside it. A rising pattern across two or more draws, especially with concurrent AFP elevation, warrants imaging (CT of chest, abdomen, and pelvis) and urgent consultation with a urologic oncologist.
• Mildly elevated, not rising: Check LH and testosterone to rule out a false positive from low testosterone or LH cross-reactivity. Consider retesting with a different assay platform. If the mild elevation persists without a clear non-tumor explanation, closer surveillance intervals are warranted.
• Post-treatment, not normalizing on schedule: If hCG is not declining along the expected half-life curve after orchiectomy or chemotherapy, residual viable tumor is likely. This typically triggers additional imaging and discussion about further treatment.
• Normal hCG but clinical suspicion persists: A normal hCG does not exclude testicular cancer. If imaging or physical exam findings are concerning, proceed with further workup regardless of marker levels. Ask whether your lab measures free beta-hCG separately, as this catches tumors that intact hCG alone misses.